(Q37385392)

20 August 2017

1 reference

title

mTOR inhibitors for hepatocellular cancer: a forward-moving target (English)

1 reference

20 August 2017

hepatocellular carcinoma

1 reference

Gerhard Treiber

1

1 reference

20 August 2017

1 February 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

247-261

1 reference

20 August 2017

2

1 reference

20 August 2017

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Diagnosis and Treatment of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Systemic treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Novel advancements in the management of hepatocellular carcinoma in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

21 January 2018

mTOR and cancer therapy

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

IRS-1: auditing the effectiveness of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

mTOR and P70 S6 kinase expression in primary liver neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Significant gene expression differences in histologically "Normal" liver biopsies: Implications for control tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.247

21 January 2018

Identifiers

DOI

10.1586/14737140.9.2.247

1 reference

20 August 2017

1 reference

PubMed ID

19192962